Loading
A phase 3 trial of Rocapuldencel-T run by Argos Therapeutics, terminated.
Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma is a phase 3 interventional study registered as NCT01582672 by Argos Therapeutics, with 462 participants enrolled, started 2012-11. Conditions recorded: Advanced Renal Cell Carcinoma, Renal Cell Carcinoma and Metastatic Renal Cell Carcinoma. Interventions recorded: Standard Treatment and AGS-003.
Shares Rocapuldencel-T, Argos Therapeutics, Renal cell carcinoma and the tag pipeline.
Shares Rocapuldencel-T, Argos Therapeutics, Renal cell carcinoma and the tag pipeline.
Shares Rocapuldencel-T, Argos Therapeutics, Renal cell carcinoma and the tag pipeline.
Shares Rocapuldencel-T, Argos Therapeutics, Renal cell carcinoma and the tag pipeline.
Shares Rocapuldencel-T, Argos Therapeutics and the tag pipeline.
Shares Rocapuldencel-T, Argos Therapeutics and the tag pipeline.
Shares Renal cell carcinoma and the tag pipeline.
Shares Renal cell carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/